company background image
ISKJ

Human Stem Cells Institute MISX:ISKJ Stock Report

Last Price

₽59.54

Market Cap

₽4.3b

7D

0%

1Y

-32.9%

Updated

05 Oct, 2022

Data

Company Financials

Public Joint-Stock Company "Human Stem Cells Institute"

MISX:ISKJ Stock Report

Mkt Cap: ₽4.3b

ISKJ Stock Overview

Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia.

ISKJ fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance1/6
Financial Health3/6
Dividends0/6

My Notes

New

Notes are coming soon

Public Joint-Stock Company "Human Stem Cells Institute" Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Human Stem Cells Institute
Historical stock prices
Current Share Price₽59.54
52 Week High₽177.00
52 Week Low₽52.52
Beta1.41
1 Month Change0%
3 Month Change1.43%
1 Year Change-32.86%
3 Year Change391.66%
5 Year Change388.03%
Change since IPO306.17%

Recent News & Updates

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Public Joint-Stock Company "Human Stem Cells Institute" (MCX:ISKJ)

May 09
Risks To Shareholder Returns Are Elevated At These Prices For Public Joint-Stock Company "Human Stem Cells Institute" (MCX:ISKJ)

Is Human Stem Cells Institute (MCX:ISKJ) Using Too Much Debt?

Dec 25
Is Human Stem Cells Institute (MCX:ISKJ) Using Too Much Debt?

We Wouldn't Rely On Human Stem Cells Institute's (MCX:ISKJ) Statutory Earnings As A Guide

Nov 19
We Wouldn't Rely On Human Stem Cells Institute's (MCX:ISKJ) Statutory Earnings As A Guide

Shareholder Returns

ISKJRU BiotechsRU Market
7D0%-1.7%0%
1Y-32.9%2.4%-38.2%

Return vs Industry: ISKJ underperformed the Russian Biotechs industry which returned -7.1% over the past year.

Return vs Market: ISKJ exceeded the Russian Market which returned -38.2% over the past year.

Price Volatility

Is ISKJ's price volatile compared to industry and market?
ISKJ volatility
ISKJ Average Weekly Movementn/a
Biotechs Industry Average Movement7.8%
Market Average Movement4.9%
10% most volatile stocks in RU Market10.2%
10% least volatile stocks in RU Market2.5%

Stable Share Price: Insufficient data to determine ISKJ's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine ISKJ's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003n/aPrikhodko Viktorovichhttps://hsci.ru

Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation.

Public Joint-Stock Company "Human Stem Cells Institute" Fundamentals Summary

How do Human Stem Cells Institute's earnings and revenue compare to its market cap?
ISKJ fundamental statistics
Market Cap₽4.29b
Earnings (TTM)₽16.94m
Revenue (TTM)₽1.14b

253.1x

P/E Ratio

3.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ISKJ income statement (TTM)
Revenue₽1.14b
Cost of Revenue₽424.68m
Gross Profit₽719.25m
Other Expenses₽702.31m
Earnings₽16.94m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.24
Gross Margin62.88%
Net Profit Margin1.48%
Debt/Equity Ratio103.9%

How did ISKJ perform over the long term?

See historical performance and comparison